According to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA), American pharmaceutical companies have 54 COPD medications in their pipelines. The list of drugs in development includes all dosage forms, including a large number of inhaled medications.
PhRMA President and CEO John J. Castellani commented, “Early detection of COPD is imperative, as effective treatment can change the course and progression of this devastating disease. The promising new therapies highlighted in this report illustrate how emerging scientific approaches to treating respiratory diseases such as COPD offer great hope to improve and save the lives of future patients.”
Read the PhRMA press release.
Read the PhRMA report on COPD drugs in development.
